Watchlist Price Alert

Cue Biopharma Inc. (CUE)

NASDAQ: CUE · Real-Time Price · USD

0.70

0.03 (4.10%)

At close: Jul 02, 2025, 3:59 PM

0.70

-0.19%

After-hours: Jul 02, 2025, 06:31 PM EDT

4.10% (1D)

Bid	0.65
Market Cap	52.84M
Revenue (ttm)	7.99M
Net Income (ttm)	-40.58M
EPS (ttm)	-0.64
PE Ratio (ttm)	-1.1
Forward PE	-1.61
Analyst	Buy

Ask	0.71
Volume	211,810
Avg. Volume (20D)	225,821
Open	0.68
Previous Close	0.67
Day's Range	0.67 - 0.71
52-Week Range	0.45 - 1.99
Beta	1.42

About CUE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CUE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cue Biopharma Inc. is scheduled to release its earnings on Aug 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

-1.45%

Cue Biopharma shares are trading higher after the ... Unlock content with Pro Subscription

1 week ago

+8.67%

Cue Biopharma shares are trading higher after the company announced it received FDA pre-IND feedback for CUE-401 autoimmune therapy.

News

1 month ago · zacks.com

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.25 per share a year ago.

2 months ago · zacks.com

Will Cue Biopharma, Inc. (CUE) Report Negative Q1 Earnings? What You Should Know

Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · seekingalpha.com

Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)

Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Busine...